The DOI matches its Crossref record; 141 of the 141 references it cites were found in a registry or an index.
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Open accessAbstract
IMPORTANCE: Cannabis and cannabinoid drugs are widely used to treat disease or alleviate symptoms, but their efficacy for specific indications is not clear. OBJECTIVE: To conduct a systematic review of the benefits and adverse events (AEs) of cannabinoids. DATA SOURCES: Twenty-eight databases from inception to April 2015. STUDY SELECTION: Randomized clinical trials of cannabinoids for the following indications: nausea and vomiting due to chemotherapy, appetite stimulation in HIV/AIDS, chronic pain, spasticity due to multiple sclerosis or paraplegia, depression, anxiety disorder, sleep disorder, psychosis, glaucoma, or Tourette syndrome. DATA EXTRACTION AND SYNTHESIS: Study quality was assessed using the Cochrane risk of bias tool. All review stages were conducted independently by 2 reviewers. Where possible, data were pooled using random-effects meta-analysis. MAIN OUTCOMES AND MEASURES: Patient-relevant/disease-specific outcomes, activities of daily living, quality of life, global impression of change, and AEs. RESULTS: A total of 79 trials (6462 participants) were included; 4 were judged at low risk of bias. Most trials showed improvement in symptoms associated with cannabinoids but these associations did not reach statistical significance in all trials. Compared with placebo, cannabinoids were associated with a greater average number of patients showing a complete nausea and vomiting response (47% vs 20%; odds ratio [OR], 3.82 [95% CI, 1.55-9.42]; 3 trials), reduction in pain (37% vs 31%; OR, 1.41 [95% CI, 0.99-2.00]; 8 trials), a greater average reduction in numerical rating scale pain assessment (on a 0-10-point scale; weighted mean difference [WMD], -0.46 [95% CI, -0.80 to -0.11]; 6 trials), and average reduction in the Ashworth spasticity scale (WMD, -0.36 [95% CI, -0.69 to -0.05]; 7 trials). There was an increased risk of short-term AEs with cannabinoids, including serious AEs. Common AEs included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, drowsiness, confusion, loss of balance, and hallucination. CONCLUSIONS AND RELEVANCE: There was moderate-quality evidence to support the use of cannabinoids for the treatment of chronic pain and spasticity. There was low-quality evidence suggesting that cannabinoids were associated with improvements in nausea and vomiting due to chemotherapy, weight gain in HIV infection, sleep disorders, and Tourette syndrome. Cannabinoids were associated with an increased risk of short-term AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mild to moderate central nervous or gastro-intestinal side effects are more common with cannabinoids than with placebo but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Medical uses of THC-based cannabinoids are associated with an increased risk of short-term adverse effects, but severe side effects are rare [13].”
From Cannabis, cannabinoids and health: a review of evidence on risks and medical benefits (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous systematic reviews have been limited in their coverage of all relevant diseases, but most importantly primarily ignored the fact that medical cannabinoid products—a term that encompasses all plant-derived and synthetic derivatives—differ in their pharmacology [1–5].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Finally, data analysis using SMD allowed the inclusion of a large variety of measurements in the evaluation of the outcomes and allowed us to include many more RCTs for all relevant medical indications than in a previous extensive meta-analysis [3].”
From Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. (2022) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence suggests that efforts to selfmanage depression with cannabis are increasing [71][72][73][74][75] (also Aaron L. Sarvet, MPH, written communication, January 2, 2018) despite lack of evidence that cannabinoids are effective for this purpose 76,77 ; prospectively, cannabis worsens the course of depressive disorders.78”
From Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States (2018) · cites this paper as [75]
In the citing paper
“Several clinical studies have demonstrated the analgesic effects of cannabinoids in human disease states, including pain associated with diabetes, chemotherapy, multiple sclerosis, and fibromyalgia (Lynch and Ware, 2015;Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“A comprehensive meta-analysis shows that medicinal cannabis and cannabinoids effectively alleviate different types of pain, such as neuropathic, fibromyalgia, multiple sclerosis, cancer, diabetic neuropathy, refractory pain due to multiple sclerosis or other neurological conditions, rheumatoid arthritis, noncancer pain, central pain, musculoskeletal problems, and chemotherapy-induced pain (Whiting”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
In the citing paper
“Although several studies show that 'medical cannabis' can improve various types of pain, cannabimimetic side effects, which include drowsiness or fatigue, dizziness, dry mouth, nausea, and cognitive effects, have also been reported (Whiting et al, 2015).”
From The endogenous cannabinoid system: a budding source of targets for treating inflammatory and neuropathic pain (2018) · cites this paper as Whiting et al, 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Quantifying heterogeneity in a meta‐analysis
Higgins, J. P. T., & Thompson, S. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1186 · Cited by 36,763
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
Cochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Interrater Reliability of a Modified Ashworth Scale of Muscle Spasticity
Bohannon, R. W., & Smith, M. B. (1987) · Physical Therapy · doi:10.1093/ptj/67.2.206 · Cited by 5,461
GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
Meta-analyses involving cross-over trials: methodological issues
Elbourne, D. R., Altman, D. G., Higgins, J. P., Curtin, F., Worthington, H. V., & Vail, A. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.140 · Cited by 2,305
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827
Research works printed but not linked: 20
- [8]8. Canadian Agency for Drugs and Technologies in Health. CADTH Peer Review Checklist for Search Strategies (Internet). Ottawa, Canada: CADTH; 2013. https://www.cadth.ca/resources/finding-evidence /cadth-peer-review-checklist-search-strategies. Accessed March 17, 2014.
- [14]14. Broder LE, Lean NL, Hilsenbeck SG. A randomized blinded clinical trial comparing delta-9-tetrahydrocannabinol (THC) and hydroxizine (HZ) as antiemetics (AE) for cancer chemotherapy (CT). Proc Am Assoc Cancer Res. 1982;23:514.
- [16]16. Hagenbach U, Luz S, Brenneisen R, Mäder M. The treatment of spasticity with D9-tetrahydrocannabinol (D9-THC) in patients with spinal cord injury. Paper presented at: IACM 2nd Conference on Cannabinoids in Medicine; September 12-13, 2003; Cologne, Germany.
- [18]18. Denver, CO. Am J Respir Crit Care Med. 2011;183(1):A2720.
- [46]46. Ungerleider JT, Andrysiak T, Fairbanks L, Goodnight J, Sarna G, Jamison K. Cannabis and cancer chemotherapy: a comparison of oral delta-9-THC and prochlorperazine. Cancer. 1982;50 (4):636-645.
- [48]48. Harden-Harrison MM, Munsell MF, Fisch MJ, et al. Dronabinol for the prevention of nausea from cyclophosphamide and/or adriamycin. Paper presented at: International MASCC/ISOO Symposium: Supportive Care in Cancer; June 28-30, 2012; New York, NY. Support Care Cancer. 2012;20:S209-S210.
- [50]50. Lane M, Vogel CL, Ferguson J, et al. Dronabinol and prochlorperazine in combination are better than either single agent alone for treatment of chemotherapy-induced nausea and vomiting. Proc Am Soc Clin Oncol. 1989;8:326.
- [52]52. Chan HS, MacLeod SM, Correia JA. Nabilone vs prochlorperazine for control of cancer chemotherapy-induced emesis in children. Proc Am Soc Clin Oncol. 1984;3:108.
- [54]54. Frytak S, Moertel CG, Ofallon JR. Comparison of delta-9-tetrahydrocannabinol (THC), prochlorperazine (PCP) and placebo as anti-emetics for cancer-chemotherapy. Proc Am Assoc Cancer Res. 1979;20:391.
- [56]56. McCabe M, Smith FP, Goldberg D, et al. Comparative trial of oral 9 tetrahydrocannabinol and prochlorperazine for cancer chemotherapy related nausea and vomiting. Proc Am Assoc Cancer Res and Am Soc Clin Oncol. 1981;22:416.
- [63]63. Ware M, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Paper presented at: Canadian Rheumatology Association Meeting; February 18-21, 2009; Kananaskis, AB: Canada. Abstract 149 J Rheumatol. 2009;36(11):2607.
- [80]80. Rog DJ, Nurmikko TJ, Friede T, Young CA. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005;65(6):812-819.
- [90]90. Abrams DI, Jay CA, Vizoso H, et al. Smoked cannabis therapy for HIV-related painful peripheral neuropathy: results of a randomized, placebo-controlled clinical trial. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands.
- [116]116. Cambridge Laboratories Ltd. A randomised, crossover, double blind comparison of the analgesic effect and patient tolerability of nabilone and dihydrocodeine in chronic neuropathic pain. metaRegister of Controlled Trials. http://isrctn.org /ISRCTN15330757. Accessed April 7, 2014.
- [136]136. Zajicek J, Reif M, Schnelle M; UK MUSEC Study Investigators. Cannabis extract in the treatment of muscle stiffness and other symptoms in multiple sclerosis -results of the MUSEC study. Paper presented at: IACM 5th Conference on Cannabinoids in Medicine; October 2-3, 2009; Cologne, Germany. 137.
- [93]93. Collin C, Ambler Z, Kent R, McCalla R. A randomised controlled study of Sativex® in patients with symptoms of spasticity due to multiple sclerosis. Paper presented at: 22nd Congress of the ECTRIMS; September 27-30, 2006; Madrid, Spain. 138. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. Paper presented at: IACM 3rd Conference on Cannabinoids in Medicine; September 9-10, 2005; Leiden, the Netherlands. 139. Center for Medicinal Cannabis Research. Short-term effects of medicinal cannabis therapy on spasticity in multiple sclerosis. ClinicalTrials.gov. http://ClinicalTrials.gov/show/NCT00248378. Accessed April 7, 2014. 140. Institut fur Klinische Forschung Germany;
- [155]155. Rohleder C, Pahlisch F, Schaefer C, et al. The endocannabinoid system as a pharmacological target for antipsychotic treatment and more? Paper presented at: 8th International Conference on Early Psychosis: From Neurobiology to Public Policy; October 11-13, 2012; San Francisco, CA. Early Interv Psychiatry. 2012;6(suppl 1):7 doi:10.1111/j.1751-7893 .2012.00392.x. · DOI
- [164]164. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. MeDRA (Medical Dictionary for Regulatory Activities). http://www .meddra.org/. Accessed September 2, 2014.
- [178]178. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids as Co-Analgesics: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health;2010.
- [179]179. Canadian Agency for Drugs and Technologies in Health (CADTH). Cannabinoids for the Management of Neuropathic Pain: Review of Clinical Effectiveness. Ottawa, Canada: Canadian Agency for Drugs and Technologies in Health);2010.
Cited by
Sorted by citations
Items 201–300 of 1,002
How Medical Marijuana Smoothed the Transition to Marijuana Legalization in the United States
Kilmer, B., & MacCoun, R. J. (2017) · Annual Review of Law and Social Science · doi:10.1146/annurev-lawsocsci-110615-084851 · Cited by 86
Modern History of Medical Cannabis: From Widespread Use to Prohibitionism and Back
Pisanti, S., & Bifulco, M. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.002 · Cited by 85
Appetite problem in cancer patients: Pathophysiology, diagnosis, and treatment
Hariyanto, T. I., & Kurniawan, A. (2021) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2021.100336 · Cited by 89
Extraction of medicinal cannabinoids through supercritical carbon dioxide technologies: A review
Qamar, S., Manrique, Y. J., Parekh, H. S., & Falconer, J. R. (2021) · Journal of Chromatography B · doi:10.1016/j.jchromb.2021.122581 · Cited by 92
Schlag, A. K., O'Sullivan, S. E., Zafar, R. R., & Nutt, D. J. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108586 · Cited by 82
Exploring Marijuana Advertising on Weedmaps, a Popular Online Directory
Bierut, T., Krauss, M. J., Sowles, S. J., & Cavazos‐Rehg, P. A. (2016) · Prevention Science · doi:10.1007/s11121-016-0702-z · Cited by 84
Cannabinoid Hyperemesis Syndrome: Reports of Fatal Cases
Nourbakhsh, M., Miller, A. C., Gofton, J., Jones, G. R., & Adeagbo, B. A. (2018) · Journal of Forensic Sciences · doi:10.1111/1556-4029.13819 · Cited by 84
Torres-Moreno, M. C., Papaseit, E., Torrens, M., & Farré, M. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.3485 · Cited by 86
Endocannabinoid System: Chemical Characteristics and Biological Activity
Rezende, B., Alencar, A. K. N., de Bem, G. F., Fontes-Dantas, F. L., & Montes, G. C. (2023) · Pharmaceuticals · doi:10.3390/ph16020148 · Cited by 108
Okusanya, B. O., Asaolu, I. O., Ehiri, J. E., Kimaru, L. J., Okechukwu, A., & Rosales, C. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01425-3 · Cited by 91
Pain management in hidradenitis suppurativa and a proposed treatment algorithm
Savage, K. T., Singh, V., Patel, Z. S., Yannuzzi, C. A., McKenzie-Brown, A. M., Lowes, M. A., & Orenstein, L. A. V. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.09.039 · Cited by 87
Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review
SANTOS, R. G. D., Hallak, J. E. C., & Crippa, J. A. S. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-57369-0_3 · Cited by 82
Wilkerson, J. L., Ghosh, S., Mustafa, M., Abdullah, R. A., Niphakis, M. J., Cabrera, R., Maldonado, R. L., Cravatt, B. F., & Lichtman, A. H. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.11.015 · Cited by 78
Zeraatkar, D., Cooper, M. A., Agarwal, A., Vernooij, R. W. M., Leung, G., Loniewski, K., Dookie, J., Ahmed, M. M., Hong, B. Y., Hong, C. J. H., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-054282 · Cited by 87
Petzke, F., Enax-Krumova, E. K., & Häuser, W. (2016) · Der Schmerz · doi:10.1007/s00482-015-0089-y · Cited by 80
Maccarrone, M., Maldonado, R. J., Casas, M., Henze, T., & Centonze, D. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1292849 · Cited by 83
Pedersen, E. R., (The Marijuana Outcomes Study Team), Huang, W., Dvorak, R. D., Prince, M. A., & Hummer, J. F. (2017) · Psychology of Addictive Behaviors · doi:10.1037/adb0000271 · Cited by 80
Medical cannabis education among healthcare trainees: A scoping review
Zolotov, Y., Metri, S., Calabria, E., & Kogan, M. (2021) · Complementary Therapies in Medicine · doi:10.1016/j.ctim.2021.102675 · Cited by 80
Naftali, T., Schleider, L. B., Almog, S., Meiri, D., & Konikoff, F. M. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab069 · Cited by 80
Han, B. H., Funk‐White, M., Ko, R., Al‐Rousan, T., & Palamar, J. J. (2021) · Journal of the American Geriatrics Society · doi:10.1111/jgs.17213 · Cited by 80
Cannabinoids as Anticancer Drugs
Ramer, R., & Hinz, B. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.04.002 · Cited by 82
Splendor in the Grass? A Pilot Study Assessing the Impact of Medical Marijuana on Executive Function
Gruber, S. A., Sagar, K. A., Dahlgren, M. K., Racine, M. T., Smith, R. T., & Lukas, S. E. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00355 · Cited by 86
New York Physicians' Perspectives and Knowledge of the State Medical Marijuana Program
Sideris, A., Khan, F., Boltunova, A., Cuff, G. E., Gharibo, C. G., & Doan, L. (2018) · Cannabis and Cannabinoid Research · doi:10.1089/can.2017.0046 · Cited by 78
Gilman, J. M., Schuster, R. M., Potter, K. W., Schmitt, W. A., Wheeler, G. L., Pachas, G. N., Hickey, S., Cooke, M. E., Dechert, A., Plummer, R. S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.2106 · Cited by 79
The potential impact of cannabis legalization on the development of cannabis use disorders
Budney, A. J., & Borodovsky, J. T. (2017) · Preventive Medicine · doi:10.1016/j.ypmed.2017.06.034 · Cited by 79
Does Cannabis Use Cause Declines in Neuropsychological Functioning? A Review of Longitudinal Studies
González, R., Pacheco‐Colón, I., Duperrouzel, J. C., & Hawes, S. W. (2017) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617717000789 · Cited by 77
Zagórska-Dziok, M., Bujak, T., Ziemlewska, A., & Nizioł‐Łukaszewska, Z. (2021) · Molecules · doi:10.3390/molecules26040802 · Cited by 80
Cannabinoid Receptor Signaling in Central Regulation of Feeding Behavior: A Mini-Review
Koch, M. (2017) · Frontiers in Neuroscience · doi:10.3389/fnins.2017.00293 · Cited by 82
Yanes, J. A., Riedel, M. C., Ray, K. L., Kirkland, A. E., Bird, R. T., Boeving, E. R., Reid, M. A., González, R., Robinson, J. L., Laird, A. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117744995 · Cited by 81
Bell, A. D., MacCallum, C., Margolese, S., Walsh, Z., Wright, P., Daeninck, P. J., Mandarino, E., Lacasse, G., Kaur Deol, J., de Freitas, L., et al. (2024) · Cannabis & Cannabinoid Research · doi:10.1089/can.2021.0156 · Cited by 78
Benefits and Harms of Plant-Based Cannabis for Posttraumatic Stress Disorder
O'Neil, M. E., Nugent, S. M., Morasco, B. J., Freeman, M., Low, A., Kondo, K. K., Zakher, B., Elven, C., Motu’apuaka, M. L., Paynter, R. A., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m17-0477 · Cited by 76
Dzierżanowski, T. (2019) · Cancers · doi:10.3390/cancers11020129 · Cited by 79
Lewis‐Bakker, M. M., Yang, Y., Vyawahare, R., & Kotra, L. P. (2019) · Cannabis and Cannabinoid Research · doi:10.1089/can.2018.0067 · Cited by 87
Iftikhar, A., Zafar, U., Ahmed, W., Shabbir, M. A., Sameen, A., Sahar, A., Bhat, Z. F., Kowalczewski, P. Ł., Jarzębski, M., & Aadil, R. M. (2021) · Molecules · doi:10.3390/molecules26247699 · Cited by 80
A Balanced Approach for Cannabidiol Use in Chronic Pain
Argueta, D. A., Ventura, C. M., Kiven, S. B., Sagi, V., & Gupta, K. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00561 · Cited by 78
Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis
Filippini, G., Minozzi, S., Borrelli, F., Cinquini, M., & Dwan, K. (2022) · Cochrane Database Systematic Reviews · doi:10.1002/14651858.cd013444.pub2 · Cited by 75
Leaner and greener analysis of cannabinoids
Mudge, E., Murch, S. J., & Brown, P. N. (2017) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-017-0256-3 · Cited by 75
Combined effects of HIV and marijuana use on neurocognitive functioning and immune status
Thames, A. D., Mahmood, Z., Burggren, A. C., Karimian, A., & Kuhn, T. P. (2015) · AIDS Care · doi:10.1080/09540121.2015.1124983 · Cited by 74
Medicinal Uses of Marijuana and Cannabinoids
Grotenhermen, F., & Müller‐Vahl, K. (2016) · Critical Reviews in Plant Sciences · doi:10.1080/07352689.2016.1265360 · Cited by 72
Cannabinoid receptor type-1: breaking the dogmas
Busquets-García, A., Gómez, E. S., Bellocchio, L., & Marsicano, G. (2016) · F1000Research · doi:10.12688/f1000research.8245.1 · Cited by 79
Moore, A., Fisher, E., Finn, D. P., Finnerup, N. B., Gilron, I., Haroutounian, S., Krane, E. J., Rice, A. S. C., Rowbotham, M. C., Wallace, M. S., et al. (2020) · Pain · doi:10.1097/j.pain.0000000000001941 · Cited by 83
Gould, J. (2015) · Nature · doi:10.1038/525s2a · Cited by 73
What Do We Know Now About the Impact of the Laws Related to Marijuana?
Maxwell, J. C., & Mendelson, B. (2016) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000188 · Cited by 73
Cannabis regulatory science: risk–benefit considerations for mental disorders
Borodovsky, J. T., & Budney, A. J. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1454406 · Cited by 75
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?
Xu, X., Shen, D., Gao, Y., Zhou, Q., Ni, Y., Meng, H., Shi, H., Le, W., Chen, S., & Chen, S. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00250-5 · Cited by 81
Cannabis Use, Lung Cancer, and Related Issues
Jett, J. R., Stone, E. C. A., Warren, G. W., & Cummings, K. M. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.013 · Cited by 73
Modulation of the Endocannabinoid System as a Potential Anticancer Strategy
Ramer, R., Schwarz, R., & Hinz, B. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00430 · Cited by 75
The Use of Medical Marijuana in Cancer
Birdsall, S., Birdsall, T. C., & Tims, L. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0530-0 · Cited by 72
Tafelski, S., Häuser, W., & Schäfer, M. (2016) · Der Schmerz · doi:10.1007/s00482-015-0092-3 · Cited by 71
Good, P., Haywood, A., Gogna, G., Martin, J. H., Yates, P., Greer, R., & Hardy, J. (2019) · BMC Palliative Care · doi:10.1186/s12904-019-0494-6 · Cited by 58
Should Cannabinoids Be Added to Multimodal Pain Regimens After Total Hip and Knee Arthroplasty?
Hickernell, T. R., Lakra, A., Berg, A. R., Cooper, H. J., Geller, J. A., & Shah, R. P. (2018) · The Journal of Arthroplasty · doi:10.1016/j.arth.2018.07.027 · Cited by 68
Turna, J., Simpson, W. S., Patterson, B. A., Lucas, P., & Ameringen, M. V. (2019) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2019.01.024 · Cited by 69
Oral manifestations of illicit drug use
Teoh, L., Moses, G., & McCullough, M. (2019) · Australian Dental Journal · doi:10.1111/adj.12709 · Cited by 69
Matowa, P. R., Gundidza, M., Gwanzura, L., & Nhachi, C. F. B. (2020) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-020-03046-8 · Cited by 74
Safety Considerations in Cannabinoid-Based Medicine
Gottschling, S., Ayonrinde, O., Bhaskar, A., Blockman, M., D’Agnone, O., Schecter, D., Rodríguez, L. D. S., Yafai, S., & Cyr, C. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s275049 · Cited by 72
de Souza, M. R., Henriques, A. T., & Limberger, R. P. (2022) · Journal of Cannabis Research · doi:10.1186/s42238-022-00142-z · Cited by 89
Wolfe, D. M., Corace, K., Butler, C., Rice, D. B., Skidmore, B., Patel, Y., Thayaparan, P., Michaud, A., Hamel, C., Smith, A., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281826 · Cited by 70
Cannabinoids for treatment of glaucoma
Novack, G. D. (2016) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000242 · Cited by 69
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
Hasenoehrl, C., Storr, M., & Schicho, R. (2017) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2017.1292851 · Cited by 69
Cannabinoids in the Management of Acute Pain: A Systematic Review and Meta-analysis
Gazendam, A., Nucci, N. W., Gouveia, K., Khalik, H. A., Rubinger, L., & Johal, H. S. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2019.0079 · Cited by 68
Patterns of Medical Cannabis Use Among Older Adults from a Cannabis Dispensary in New York State
Kaufmann, C. N., Kim, A., Miyoshi, M., & Han, B. H. (2020) · Cannabis and Cannabinoid Research · doi:10.1089/can.2020.0064 · Cited by 68
Use of Cannabis and Cannabinoids for Treatment of Cancer
Cherkasova, V., Wang, B., Gerasymchuk, M., Fiselier, A., Kovalchuk, O., & Kovalchuk, I. (2022) · Cancers · doi:10.3390/cancers14205142 · Cited by 70
The current status of artisanal cannabis for the treatment of epilepsy in the United States
Sulak, D., Saneto, R. P., & Goldstein, B. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2016.12.032 · Cited by 69
Chemical and Physical Elicitation for Enhanced Cannabinoid Production in Cannabis
Gorelick, J., & Bernstein, N. (2017) · Springer eBooks · doi:10.1007/978-3-319-54564-6_21 · Cited by 68
Provider Perspectives on Use of Medical Marijuana in Children With Cancer
Ananth, P. J., Ma, C., Al‐Sayegh, H., Kroon, L., Klein, V., Wharton, C. M., Hallez, E., Braun, I. M., Michelson, K. N., Rosenberg, A. R., et al. (2017) · PEDIATRICS · doi:10.1542/peds.2017-0559 · Cited by 67
Marijuana Use and Mortality following Orthopedic Surgical Procedures
Moon, A. S., Smith, W. R., Mullen, S., Ponce, B. A., McGwin, G., Shah, A. B., & Naranje, S. M. (2018) · Substance Abuse · doi:10.1080/08897077.2018.1449054 · Cited by 67
Bradford, A. C., & Bradford, W. D. (2018) · The Journal of Law and Economics · doi:10.1086/699620 · Cited by 67
Watson, C. W., Paolillo, E. W., Morgan, E. E., Umlauf, A., Sundermann, E. E., Ellis, R. J., Letendre, S. L., Marcotte, T. D., Heaton, R. K., & Grant, I. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002211 · Cited by 66
Cannabis‐related allergies: An international overview and consensus recommendations
Skypala, I. J., Jeimy, S. B., Brucker, H., Nayak, A. P., Decuyper, I. I., Bernstein, J. A., Connors, L. A., Kanani, A. S., Klimek, L., Lo, S. C. R., et al. (2022) · Allergy · doi:10.1111/all.15237 · Cited by 73
Review: Cannabinoids as Medicinals
Khalsa, J. H., Bunt, G. C., Blum, K., Maggirwar, S. B., Galanter, M. S., & Potenza, M. N. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00438-3 · Cited by 72
Botanical Drugs as an Emerging Strategy in Inflammatory Bowel Disease: A Review
Algieri, F., Rodríguez‐Nogales, A., Rodríguez‐Cabezas, M. E., Risco, S., Ocete, M. A., & Gálvez, J. (2015) · Mediators of Inflammation · doi:10.1155/2015/179616 · Cited by 67
Nicholas, L. H., & Maclean, J. C. (2019) · Journal of Policy Analysis and Management · doi:10.1002/pam.22122 · Cited by 65
Atsmon, J., Heffetz, D., Deutsch, L., Deutsch, F., & Sacks, H. (2017) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.408 · Cited by 69
Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials
SANTOS, R. G. D., Guimarães, F. S., Crippa, J. A. S., Hallak, J. E. C., Rossi, G. N., Rocha, J. M., & Zuardi, A. W. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1754793 · Cited by 76
Caulkins, J. P., Kilmer, B., & R.Kleiman, M. A. (2016) · doi:10.1093/wentk/9780190262419.001.0001 · Cited by 67
Mendiguren, A., Aostri, E., & Pineda, J. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.11.029 · Cited by 68
Effects of cannabinoid administration for pain: A meta-analysis and meta-regression.
Yanes, J. A., McKinnell, Z. E., Reid, M. A., Busler, J. N., Michel, J. S., Pangelinan, M. M., Sutherland, M. T., Younger, J., González, R., & Robinson, J. L. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000281 · Cited by 68
Meet Your Stress Management Professionals: The Endocannabinoids
deRoon‐Cassini, T. A., Stollenwerk, T. M., Beatka, M. J., & Hillard, C. J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.07.002 · Cited by 67
Therapeutic Use of Cannabis and Cannabinoids
Hsu, M., Shah, A., Jordan, A., Gold, M. S., & Hill, K. P. (2025) · JAMA · doi:10.1001/jama.2025.19433 · Cited by 73
Goldenberg, M., Reid, M. W., IsHak, W. W., & Danovitch, I. (2017) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2016.12.030 · Cited by 69
Topical Medical Cannabis: A New Treatment for Wound Pain—Three Cases of Pyoderma Gangrenosum
Maida, V., & Corban, J. P. A. H. (2017) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2017.06.005 · Cited by 66
Marijuana Promotion Online: an Investigation of Dispensary Practices
Cavazos‐Rehg, P. A., Krauss, M. J., Cahn, E. S., Lee, K. E., Ferguson, E. G., Rajbhandari, B., Sowles, S. J., Floyd, G. M., Berg, C. J., & Bierut, L. J. (2018) · Prevention Science · doi:10.1007/s11121-018-0889-2 · Cited by 66
The Use of Complementary and Alternative Medicine in Patients With Inflammatory Bowel Disease.
Lin, S. C., & Cheifetz, A. S. (2018) · Europe PMC (PubMed Central) · Cited by 66
Cannabis for the treatment of Crohn's disease
Kafil, T. S., Nguyen, T. M., MacDonald, J. K., & Chande, N. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012853.pub2 · Cited by 66
Real World Evidence in Medical Cannabis Research
Banerjee, R., Erridge, S., Salazar, O., Mangal, N., Couch, D., Pacchetti, B., & Sodergren, M. H. (2021) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-021-00346-0 · Cited by 65
Rabgay, K., Waranuch, N., Chaiyakunapruk, N., Sawangjit, R., Ingkaninan, K., & Dilokthornsakul, P. (2019) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2019.07.015 · Cited by 69
Do recreational cannabis users, unlicensed and licensed medical cannabis users form distinct groups?
Sznitman, S. R. (2017) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2016.11.010 · Cited by 64
Cannabinoids concentration variability in cannabis olive oil galenic preparations
Carcieri, C., Tomasello, C., Simiele, M., Nicolò, A. D., Avataneo, V., Canzoneri, L., Cusato, J., Perri, G. D., & D’Avolio, A. (2017) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12845 · Cited by 64
Potential Adverse Drug Events with Tetrahydrocannabinol (THC) Due to Drug–Drug Interactions
Brown, J. D. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040919 · Cited by 64
Lichenstein, S. D., Manco, N., Cope, L. M., Egbo, L., Garrison, K. A., Hardee, J., Hillmer, A. T., Reeder, K., Stern, E. F., Worhunsky, P., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-021-01226-9 · Cited by 63
Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer’s Disease
Liu, C. S., Chau, S. A., Ruthirakuhan, M. T., Lanctôt, K. L., & Herrmann, N. (2015) · CNS Drugs · doi:10.1007/s40263-015-0270-y · Cited by 63
Cannabis Epidemiology: A Selective Review
Anthony, J. C., Lopez‐Quintero, C., & Alshaarawy, O. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160813214023 · Cited by 66
Cannabinoids for the treatment of rheumatic diseases — where do we stand?
Katz, D., Katz, I., Porat-Katz, B.-S., & Shoenfeld, Y. (2018) · Nature Reviews Rheumatology · doi:10.1038/s41584-018-0025-5 · Cited by 68
Assessment of Medical Cannabis and Health-Related Quality of Life
Arkell, T. R., Downey, L. A., Hayley, A. C., & Roth, S. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.12522 · Cited by 62
Integrative Therapies in Cancer Care: An Update on the Guidelines
Gowin, K. L., Muminovic, M., Zick, S. M., Lee, R. T., Lacchetti, C., & Mehta, A. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_431554 · Cited by 63
Preliminary Evidence on Cannabis Effectiveness and Tolerability for Adults With Tourette Syndrome
Abi‐Jaoude, E., Chen, L., Cheung, P., Bhikram, T., & Sandor, P. (2017) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.16110310 · Cited by 62
The Form and Content of Cannabis Products in the United States
Steigerwald, S., Wong, P. O., Khorasani, A., & Keyhani, S. (2018) · Journal of General Internal Medicine · doi:10.1007/s11606-018-4480-0 · Cited by 62
Sagar, K. A., & Gruber, S. A. (2018) · International Review of Psychiatry · doi:10.1080/09540261.2018.1460334 · Cited by 64
Diverse TRPV1 responses to cannabinoids
Starkus, J. G., Jansen, C., Shimoda, L. M. N., Stokes, A. J., Small-Howard, A. L., & Turner, H. C. (2019) · Channels · doi:10.1080/19336950.2019.1619436 · Cited by 62
The use of cannabis in supportive care and treatment of brain tumor
Likar, R., & Nahler, G. (2017) · Neuro-Oncology Practice · doi:10.1093/nop/npw027 · Cited by 61
Metadata
- Authors
- Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., Schmidlkofer, S., Westwood, M., & Kleijnen, J.
- Affiliations
- University Hospitals Bristol NHS Foundation Trust (GB)
- Kleijnen Systematic Reviews (United Kingdom) (GB)
- Department of Medical, Oral, and Biotechnological Sciences, University “G. D'Annunzio” of Chieti-Pescara, Chieti, Italy5Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
- Medical School, Universidad Peruana de Ciencias Aplicadas (UPC), Lima, Peru7Health Outcomes and Clinical Epidemiology Section, Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio
- Radboud University Medical Center (NL)
- Institut für Epidemiologie und kongenitale Erkrankungen, Cepicon GmbH, Hamburg, Germany
- Maastricht University (NL)
- ORCID
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-06-23
- Volume
- 313
- Issue
- 24
- Pages
- 2456
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2120227293
- Semantic Scholar
- 029bce497e0633eb2a7895cfd3b315f9c462dd5f
- Cited by
- 2,169
- References
- 137
- Citations by year
- 2026: 119 · 2025: 166 · 2024: 168 · 2023: 200 · 2022: 220 · 2021: 262 · 2020: 272 · 2019: 230 · 2018: 209 · 2017: 159 · 2016: 131 · 2015: 33
- FWCI
- 22.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Bristol Research (University of Bristol) (publishedVersion)
- Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Americanae (AECID Library) (submittedVersion, other-oa)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Explore Bristol Research (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Keywords
- cannabinoids, medical cannabis, nausea and vomiting, chemotherapy-induced nausea, chronic pain, spasticity, multiple sclerosis, depression, anxiety, sleep disorders, psychosis, glaucoma, Tourette syndrome, adverse events, quality of life, activities of daily living, risk of bias, placebo comparison
- MeSH terms
- Anorexia, Mental Disorders, Cannabinoids, Tourette Syndrome, Glaucoma, Humans, Muscle Spasticity, Nausea, Randomized Controlled Trials as Topic, Chronic Pain, Medical Marijuana
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
